Lipid-lowering response to statins is affected by CYP3A5 polymorphism

Pharmacogenetics

Volumn 14, Issue 8, 2004, Pages 523-525

  Kivistö, Kari T ^a   Niemi, Mikko ^a   Schaeffeler, Elke ^a   Pitkälä, Kaisu ^b   Tilvis, Reijo ^b   Fromm, Martin F ^a   Schwab, Matthias ^a   Eichelbaum, Michel ^a   Strandberg, Timo ^b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cholesterol; CYP3A5; LDL; Statin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CYTOCHROME P450 3A5; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TOLBUTAMIDE;

AGED; ALLELE; ARTICLE; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; HYPOLIPEMIA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, LDL; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HEPTANOIC ACIDS; HOMOZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MALE; POLYMORPHISM, GENETIC; PYRROLES; SIMVASTATIN;

EID: 4143049054     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fpc.0000114762.78957.a5     Document Type: Article

References (13)

1. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 1999; 27:173-179.
2. Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, et al. In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25:1191-1199.
3. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 2000; 28:1369-1378.
4. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet 2001; 27:383-391.
5. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11:773-779.
6. Thummel KE. Does the CYP3A5*3 polymorphism affect in vivo drug elimination? Pharmacogenetics 2003; 13:585-587.
7. Williams JA, Cook J, Hurst SI. A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos 2003; 31:1526-1530.
8. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74:245-254.
9. Strandberg TE, Pitkala K, Berglind S, Nieminen MS, Tilvis RS. Possibilities of multifactorial cardiovascular disease prevention in patients aged 75 and older: a randomized controlled trial. Drugs and Evidence Based Medicine in the Elderly (DEBATE) Study. Eur Heart J 2003; 24:1216-1222.
10. King BP, Leathart JB, Mutch E, Williams FM, Daly AK. CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol 2003; 55:625-629.
11. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81:582-587.
12. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341:498-511.
13. Williams ML, Morris MT II, Ahmad U, Yousseff M, Li W, Ertel N, for the VANJHCS research group. Veterans Affairs of New Jersey Healthcare System. Racial differences in compliance with NCEP-II recommendations for secondary prevention at a Veterans Affairs medical center. Ethn Dis 2002; 12(suppl 1):58-62.